(Boursier.com) — In trading, the share DBV Technologies jumped 11% to 3.33 euros. DBV Technologies has indeed announced the publication by the New England Journal of Medicine of data from the Epitope phase 3 study evaluating Viaskin Peanut in children aged 1 to 3 years.
Study results demonstrated that Epicutaneous Immunotherapy Treatment (EPIT) with Viaskin Peanut was statistically superior to placebo in desensitizing children to peanut by increasing the peanut dose triggering allergic symptoms. These data are considered “very good news” for children of this age group, allergic to peanuts. Indeed, there are currently no approved treatment options for children with peanut allergy under 4 years of age.
“The Epitope data is a significant advance because it could provide the first-ever FDA-approved treatment option for children ages 1 to 3 years old with peanut allergy,” comments Matthew Greenhawt, MD, MBA, MSc of the Children’s Hospital of Colorado and lead author of the publication.
©2023 Boursier.com